Product Details of 17696-11-6In 2022 ,《Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands》 appeared in Journal of Medicinal Chemistry. The author of the article were Zhao, Hong-Yi; Wang, Hai-Peng; Mao, Yu-Ze; Zhang, Hao; Xin, Minhang; Xi, Xiao-Xiao; Lei, Hao; Mao, Shuai; Li, Dong-Hui; Zhang, San-Qi. The article conveys some information:
To overcome the intractable problem of drug resistance, proteolysis targeting chimeras (PROTACs) targeting EGFR mutants were developed by optimizing covalent EGFR ligands. Covalent or reversible covalent pyrimidine- or purine-containing PROTACs were designed, synthesized, and evaluated. As a consequence, covalent PROTAC I, with a novel purine-containing EGFR ligand, was discovered as a highly potent degrader against EGFRL858R/T790M and EGFRdel19, reaching the lowest DC50 values among all reported EGFR-targeting PROTACs. Furthermore, I exhibited excellent cellular activity against the H1975 and HCC827 cell lines with high selectivity. Mechanism investigation indicated that the lysosome was involved in the degradation process. Importantly, the covalent binding strategy was proven to be an effective approach for the design of PROTACs targeting EGFRL858R/T790M, which laid the practical foundation for further development of potent EGFR-targeting PROTACs. After reading the article, we found that the author used 8-Bromooctanoic acid(cas: 17696-11-6Product Details of 17696-11-6)
8-Bromooctanoic acid(cas: 17696-11-6) acid is used in the synthesis of 8-(N-Methyl-4,4′-bipyridinyl)- octanoic acid. 8-Mercaptooctanoic acid was prepared from 8-bromooctanoic acid. And 8-Bromooctanoic Acid is a useful compound for sonodynamic therapy.Product Details of 17696-11-6
Referemce:
Bromide – Wikipedia,
bromide – Wiktionary